| abstract |
The present disclosure provides methods for predicting the sensitivity (e.g., responsiveness) of a cell and/or biological sample obtained from a subject to treatment with a histone deacetylase (HDAC) inhibitor. Such methods may comprise detecting the expression of one or more biomarkers including, one or more miRNAs (e.g., one or more of miR-17, miR-20a, miR18a, miR19a, miR-19b or miR92a) and/or c-myc and/or the presence of a c-myc amplification (e.g., 3, 4, 5, 6,7, 8, 9 or 10 copies of c-myc per cell), in the cell and/or biological sample. |